The many different faces of major depression: It is time for personalized medicine

European Journal of Pharmacology

Volumn 753, Issue , 2015, Pages 88-104

  Korte, S Mechiel ^a   Prins, Jolanda ^a   Krajnc, Anne M ^a   Hendriksen, Hendrikus ^a   Oosting, Ronald S ^a   Westphal, Koen G ^a   Korte Bouws, Gerdien A H ^a   Olivier, Berend ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Depression; Dopamine DOV 216,303; Intracranial self stimulation; Methylphenidate; Microdialysis

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE; DOPAMINE NOREPINEPHRINE REUPTAKE INHIBITOR; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; MILNACIPRAN; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NOMIFENSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; NEUROTRANSMITTER UPTAKE INHIBITOR;

ARTICLE; BRAIN DEPTH STIMULATION; BRAIN REGION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FEEDBACK SYSTEM; HISTORY OF MEDICINE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REWARD; RISK FACTOR; TREATMENT INDICATION; ANIMAL; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; ENDOPHENOTYPE; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; ENDOPHENOTYPES; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; PRECISION MEDICINE; REWARD;

EID: 84925687708     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.11.045     Document Type: Article

References (219)

1. R.E. Adamec Hypothalamic and extrahypothalamic substrates of predatory attack. Suppression and the influence of hunger Brain Res. 106 1976 57 69
2. G.K. Aghajanian, J.S. Sprouse, P. Sheldon, and K. Rasmussen Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms Ann. N. Y. Acad. Sci. 600 1990 93 103 (Discussion 103)
3. A. Andreasson, L. Arborelius, C. Erlanson-Albertsson, and M. Lekander A putative role for cytokines in the impaired appetite in depression Brain Behav. Immun. 21 2007 147 152
4. A.F. Arnsten Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms Prog. Brain Res. 126 2000 183 192
5. A.F. Arnsten Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction CNS Drugs 23 Suppl 1 2009 S33 S41
6. Association of American Psychiatry Diagnostic and Statistical Manual of Mental Disorders 5th edition 2013 DSM 5
7. J. Axelrod, and R. Tomchick Increased rate of metabolism of epinephrine and norepinephrine by sympathomimetic amines J. Pharmacol. Exp. Ther. 130 1960 367 369
8. J. Axelrod, L.G. Whitby, and G. Hertting Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues Science 133 1961 383 384
9. E.C. Azmitia Jr.; and B.S. McEwen Corticosterone regulation of tryptophan hydroxylase in midbrain of the rat Science 166 1969 1274 1276
10. D.S. Baldwin, and G.I. Papakostas Symptoms of fatigue and sleepiness in major depressive disorder J. Clin. Psychiatry 67 Suppl 6 2006 S9 S15
11. C.M. Banki Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders J. Neurochem. 28 1977 255 257
12. N. Bel, and F. Artigas Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei Synapse 15 1993 243 245
13. B. Beer, J. Stark, P. Krieter, P. Czobor, G. Beer, A. Lippa, and P. Skolnick DOV 216,303, a triple reuptake inhibitor: safety, tolerability, and pharmacokinetic profile J. Clin. Pharmacol. 44 2004 1360 1367
14. J. Bergman, B.K. Madras, S.E. Johnson, and R.D. Spealman Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys J. Pharmacol. Exp. Ther. 251 1989 150 155
15. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
16. C.W. Berridge, and B.D. Waterhouse The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes Brain Res. Brain Res. Rev. 42 2003 33 84
17. K.C. Berridge, and M.L. Kringelbach Affective neuroscience of pleasure: reward in humans and animals Psychopharmacology 199 2008 457 480
18. R.A. Bevins, J.L. Wilkinson, M.I. Palmatier, H.L. Siebert, and S.M. Wiltgen Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats Psychopharmacology 184 2006 470 481
19. E.Y. Bijlsma, J.S. Chan, B. Olivier, J.G. Veening, M.J. Millan, M.D. Waldinger, and R.S. Oosting Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol. Biochem. Behav. 121 2014 88 101
20. J.C. Bittencourt, F. Presse, C. Arias, C. Peto, J. Vaughan, J.L. Nahon, W. Vale, and P.E. Sawchenko The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization J. Comp. Neurol. 319 1992 218 245
21. R.D. Blakely, A. Ortega, and M.B. Robinson The brain in flux: genetic, physiologic, and therapeutic perspectives on transporters in the CNS Neurochem. Int. 73 2014 1 3
22. P. Blier, C. de Montigny, and Y. Chaput Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression J. Clin. Psychopharmacol. 7 1987 24S 35S
23. P. Blier, and C. de Montigny Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: single-cell recording studies J. Clin. Psychopharmacol. 10 1990 13S 20S
24. P. Blier Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins Naunyn Schmiedebergs Arch. Pharmacol. 344 1991 160 166
25. P. Blier Altered function of the serotonin 1A autoreceptor and the antidepressant response Neuron 65 2010 1 2
26. P.F. Bouvy, and M. Liem Antidepressants and lethal violence in the Netherlands 1994-2008 Psychopharmacology 222 2012 499 506
27. M.E. Breuer, J.S. Chan, R.S. Oosting, L. Groenink, S.M. Korte, U. Campbell, R. Schreiber, T. Hanania, E.M. Snoeren, M. Waldinger, and B. Olivier The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects Eur. Neuropsychopharmacol. 18 2008 908 916
28. J.A. Bridge, S. Iyengar, C.B. Salary, R.P. Barbe, B. Birmaher, H.A. Pincus, L. Ren, and D.A. Brent Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials J. Am. Med. Assoc. 297 2007 1683 1696
29. K. Bulloch, and W. Pomerantz Autonomic nervous system innervation of thymic-related lymphoid tissue in wildtype and nude mice J. Comp. Neurol. 228 1984 57 68
30. B.J. Caldarone, N.E. Paterson, J. Zhou, D. Brunner, A.P. Kozikowski, K.G. Westphal, G.A. Korte-Bouws, J. Prins, S.M. Korte, B. Olivier, and A. Ghavami The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties J. Pharmacol. Exp. Ther. 335 2010 762 770
31. L. Capuron, and A.H. Miller Immune system to brain signaling: neuropsychopharmacological implications Pharmacol. Ther. 130 2011 226 238
32. L. Capuron, G. Pagnoni, D.F. Drake, B.J. Woolwine, J.R. Spivey, R.J. Crowe, J.R. Votaw, M.M. Goodman, and A.H. Miller Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration Arch. Gen. Psychiatry 69 2012 1044 1053
33. W.A. Carlezon Jr.; and E.H. Chartoff Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation Nat. Protoc. 2 2007 2987 2995
34. B.J. Carroll, M. Feinberg, J.F. Greden, J. Tarika, A.A. Albala, R.F. Haskett, N.M. James, Z. Kronfol, N. Lohr, M. Steiner, J.P. de Vigne, and E. Young A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility Arch. Gen. Psychiatry 38 1981 15 22
35. I. Ceglia, S. Acconcia, C. Fracasso, M. Colovic, S. Caccia, and R.W. Invernizzi Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors Br. J. Pharmacol. 142 2004 469 478
36. Y. Chaput, C. de Montigny, and P. Blier Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat Neuropsychopharmacology 5 1991 219 229
37. L.G. Chepenik, C. Fredericks, X. Papademetris, L. Spencer, C. Lacadie, F. Wang, B. Pittman, J.S. Duncan, L.H. Staib, R.S. Duman, J. Gelernter, and H.P. Blumberg Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder Neuropsychopharmacology 34 2009 944 951
38. G. Chuluunkhuu, N. Nakahara, S. Yanagisawa, and I. Kamae The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes Kobe J. Med. Sci. 54 2008 E147 E158
39. G.E. Clerc, P. Ruimy, and J. Verdeau-Palles A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group Int. Clin. Psychopharmacol. 9 1994 139 143
40. M.S. Cousins, H.M. Stamat, and H. de Wit Acute doses of d-amphetamine and bupropion increase cigarette smoking Psychopharmacology 157 2001 243 253
41. J.F. Cryan, A.W. Bruijnzeel, K.L. Skjei, and A. Markou Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat Psychopharmacology 168 2003 347 358
42. R. Dantzer, L. Capuron, M.R. Irwin, A.H. Miller, H. Ollat, V.H. Perry, S. Rousey, and R. Yirmiya Identification and treatment of symptoms associated with inflammation in medically ill patients Psychoneuroendocrinology 33 2008 18 29
43. R.J. Davidson, D.A. Lewis, L.B. Alloy, D.G. Amaral, G. Bush, J.D. Cohen, W.C. Drevets, M.J. Farah, J. Kagan, J.L. McClelland, S. Nolen-Hoeksema, and B.S. Peterson Neural and behavioral substrates of mood and mood regulation Biol. Psychiatry 52 2002 478 502
44. C. de Montigny, Y. Chaput, and P. Blier Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers J. Clin. Psychiatry 51 Suppl B 1990 S4 S8
45. F.S. Dhabhar, W.B. Malarkey, E. Neri, and B.S. McEwen Stress-induced redistribution of immune cells - from barracks to boulevards to battlefields: a tale of three hormones - Curt Richter Award winner Psychoneuroendocrinology 37 2012 1345 1368
46. N. Dillier, J. Laszlo, B. Muller, W.P. Koella, and H.R. Olpe Activation of an inhibitory noradrenergic pathway projecting from the locus coeruleus to the cingulate cortex of the rat Brain Res. 154 1978 61 68
47. R.S. Duman Role of neurotrophic factors in the etiology and treatment of mood disorders Neuromol. Med. 5 2004 11 25
48. R.S. Duman, and N. Li A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists Philos. Trans. R. Soc. Lond. B: Biol. Sci. 367 2012 2475 2484
49. B.W. Dunlop, P. Crits-Christoph, D.L. Evans, J. Hirschowitz, H.B. Solvason, K. Rickels, S.J. Garlow, R.J. Gallop, and P.T. Ninan Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study J. Clin. Psychopharmacol. 27 2007 614 619
50. B.W. Dunlop, and C.B. Nemeroff The role of dopamine in the pathophysiology of depression Arch. Gen. Psychiatry 64 2007 327 337
51. I.J. Elenkov, and G.P. Chrousos Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease Trends Endocrinol. Metab. 10 1999 359 368
52. D. Engblom, M. Ek, A. Ericsson-Dahlstrand, and A. Blomqvist Activation of prostanoid EP(3) and EP(4) receptor mRNA-expressing neurons in the rat parabrachial nucleus by intravenous injection of bacterial wall lipopolysaccharide J. Comp. Neurol. 440 2001 378 386
53. P. Esper, and D. Heidrich Symptom clusters in advanced illness Semin. Oncol. Nurs. 21 2005 20 28
54. J.C. Felger, L. Li, P.J. Marvar, B.J. Woolwine, D.G. Harrison, C.L. Raison, and A.H. Miller Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations Brain Behav. Immun. 31 2013 153 160
55. J.C. Felger, and A.H. Miller Neurotherapeutic implications of brain-immune interactions Neuropsychopharmacology 39 2014 242 243
56. J.D. Fernstrom, and R.J. Wurtman Brain serotonin content: physiological dependence on plasma tryptophan levels Science 173 1971 149 152
57. A.J. Flint, S.E. Black, I. Campbell-Taylor, G.F. Gailey, and C. Levinton Abnormal speech articulation, psychomotor retardation, and subcortical dysfunction in major depression J. Psychiatr. Res. 27 1993 309 319
58. S.B. Floresco, A.R. West, B. Ash, H. Moore, and A.A. Grace Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission Nat. Neurosci. 6 2003 968 973
59. J.C. Fournier, R.J. DeRubeis, S.D. Hollon, S. Dimidjian, J.D. Amsterdam, R.C. Shelton, and J. Fawcett Antidepressant drug effects and depression severity: a patient-level meta-analysis J. Am. Med. Assoc. 303 2010 47 53
60. E. Fries, L. Dettenborn, and C. Kirschbaum The cortisol awakening response (CAR): facts and future directions Int. J. Psychophysiol. 72 2009 67 73
61. R.W. Fuller, S.K. Hemrick-Luecke, and H.D. Snoddy Fluoxetine at anorectic doses does not have properties of a dopamine uptake inhibitor J. Neural Transm. Gen. Sect. 96 1994 165 177
62. J.M. Fuster The prefrontal cortex - an update: time is of the essence Neuron 30 2001 319 333
63. P.W. Gold, and G.P. Chrousos The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences Proc. Assoc. Am. Physicians 111 1999 22 34
64. P.W. Gold, and G.P. Chrousos Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states Mol. Psychiatry 7 2002 254 275
65. J.F. Goldberg, K.E. Burdick, and C.J. Endick Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression Am. J. Psychiatry 161 2004 564 566
66. R. Gowrishankar, M.K. Hahn, and R.D. Blakely Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders Neurochem. Int. 73 2014 42 48
67. A.A. Grace Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 41 1991 1 24
68. B.P. Guiard, M. El Mansari, and P. Blier Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors Curr. Drug Targets 10 2009 1069 1084
69. C. Gundlah, S. Hjorth, and S.B. Auerbach Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment Neuropharmacology 36 1997 475 482
70. S. Gupta, J.L. Vincent, and B. Frank Pramipexole: augmentation in the treatment of depressive symptoms CNS Spectr. 11 2006 172 175
71. N. Haddjeri, B. Seletti, F. Gilbert, C. de Montigny, and P. Blier Effect of ergotamine on serotonin-mediated responses in the rodent and human brain Neuropsychopharmacology 19 1998 365 380
72. M.J. Hansard, L.A. Smith, M.J. Jackson, S.C. Cheetham, and P. Jenner Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates J. Pharmacol. Exp. Ther. 303 2002 952 958
73. C. Henry, and J. Demotes-Mainard SSRIs, suicide and violent behavior: is there a need for a better definition of the depressive state? Curr. Drug Saf. 1 2006 59 62
74. J.P. Henry, and D. Scherman Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles Biochem. Pharmacol. 38 1989 2395 2404
75. M.E. Hernandez, D. Mendieta, M. Perez-Tapia, R. Bojalil, I. Estrada-Garcia, S. Estrada-Parra, and L. Pavon Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder Clin. Dev. Immunol. 2013 2013 267871
76. G. Herting, J. Axelrod, and L.G. Whitby Effect of drugs on the uptake and metabolism of H3-norepinephrine J. Pharmacol. Exp. Ther. 134 1961 146 153
77. E. Horwath, J. Johnson, M.M. Weissman, and C.D. Hornig The validity of major depression with atypical features based on a community study J. Affect. Disord. 26 1992 117 125
78. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 2006 860 867
79. T. Ishizuka, Y. Sakamoto, T. Sakurai, and A. Yamatodani Modafinil increases histamine release in the anterior hypothalamus of rats Neurosci. Lett. 339 2003 143 146
80. P.M. Johnson, and P.J. Kenny Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats Nat. Neurosci. 13 2010 635 641
81. H. Karst, S. Berger, M. Turiault, F. Tronche, G. Schutz, and M. Joels Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone Proc. Natl. Acad. Sci. USA 102 2005 19204 19207
82. S. Kasper, Y. Pletan, A. Solles, and A. Tournoux Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results Int. Clin. Psychopharmacol. 11 Suppl. 4 1996 S35 S39
83. I. Kass, and E.C. Brown Treatment of hypertensive patients with Rauwolfia compounds and reserpine; depressive and psychotic changes J. Am. Med. Assoc. 159 1955 1513 1516
84. P.J. Kenny Brain reward systems and compulsive drug use Trends Pharmacol. Sci. 28 2007 135 141
85. P.J. Kenny Common cellular and molecular mechanisms in obesity and drug addiction Nat. Rev. Neurosci. 12 2011 638 651
86. P.J. Kenny, S.A. Chen, O. Kitamura, A. Markou, and G.F. Koob Conditioned withdrawal drives heroin consumption and decreases reward sensitivity J. Neurosci. 26 2006 5894 5900
87. P.J. Kenny, F. Gasparini, and A. Markou Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats J. Pharmacol. Exp. Ther. 306 2003 1068 1076
88. M.A. Kheirbek, K.C. Klemenhagen, A. Sahay, and R. Hen Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders Nat. Neurosci. 15 2012 1613 1620
89. M. Koenigs, and J. Grafman The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex Behav. Brain Res. 201 2009 239 243
90. S.H. Kollins Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient J. Clin. Psychiatry 64 Suppl. 11 2003 S14 S18
91. G.F. Koob, and N.D. Volkow Neurocircuitry of addiction Neuropsychopharmacology 35 2010 217 238
92. I.J. Kopin Monoamine oxidase and catecholamine metabolism J. Neural. Transm. Suppl. 41 1994 57 67
93. S.M. Korte, B. Buwalda, O. Meijer, E.R. De Kloet, and B. Bohus Socially defeated male rats display a blunted adrenocortical response to a low dose of 8-OH-DPAT Eur. J. Pharmacol. 272 1 1995 45 50
94. S.M. Korte Corticosteroids in relation to fear, anxiety and psychopathology Neurosci. Biobehav. Rev. 25 2001 117 142
95. S.M. Korte, J.M. Koolhaas, J.C. Wingfield, and B.S. McEwen The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease Neurosci. Biobehav. Rev. 29 1 2005 3 38
96. G.A. Korte-Bouws, S.M. Korte, E.R. De Kloet, and B. Bohus Blockade of corticosterone synthesis reduces serotonin turnover in the dorsal hippocampus of the rat as measured by microdialysis J. Neuroendocrinol. 8 1996 877 881
97. G.S. Kranz, S. Kasper, and R. Lanzenberger Reward and the serotonergic system Neuroscience 166 2010 1023 1035
98. M.J. Kuhar, M.C. Ritz, and J.W. Boja The dopamine hypothesis of the reinforcing properties of cocaine Trends Neurosci. 14 1991 299 302
99. F. Lamers, P. de Jonge, W.A. Nolen, J.H. Smit, F.G. Zitman, A.T. Beekman, and B.W. Penninx Identifying depressive subtypes in a large cohort study: results from the Netherlands study of depression and anxiety (NESDA) J. Clin. Psychiatry 71 2010 1582 1589
100. K.A. Lapidus, C.F. Levitch, A.M. Perez, J.W. Brallier, M.K. Parides, L. Soleimani, A. Feder, D.V. Iosifescu, D.S. Charney, and J.W. Murrough A randomized controlled trial of intranasal ketamine in major depressive disorder Biol. Psychiatry S0006 3223 14 2014 (00227-3)
101. K. Lee, and C. Kornetsky Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation Pharmacol. Biochem. Behav. 60 1998 539 544
102. N.J. Leith, and R.J. Barrett Amphetamine and the reward system: evidence for tolerance and post-drug depression Psychopharmacologia 46 1976 19 25
103. S. Leknes, and I. Tracey A common neurobiology for pain and pleasure Nat. Rev. Neurosci. 9 2008 314 320
104. A.I. Leshner, and G.F. Koob Drugs of abuse and the brain Proc. Assoc. Am. Physicians 111 1999 99 108
105. R.D. Levitan, A. Lesage, S.V. Parikh, P. Goering, and S.H. Kennedy Reversed neurovegetative symptoms of depression: a community study of Ontario Am. J. Psychiatry 154 1997 934 940
106. C. Li, W.G. Brake, R.D. Romeo, J.C. Dunlop, M. Gordon, R. Buzescu, A.M. Magarinos, P.B. Allen, P. Greengard, V. Luine, and B.S. McEwen Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice Proc. Natl. Acad. Sci. USA 101 2004 2185 2190
107. C.T. Li, C.P. Lin, K.H. Chou, I.Y. Chen, J.C. Hsieh, C.L. Wu, W.C. Lin, and T.P. Su Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study NeuroImage 50 2010 347 356
108. D. Lin, G.F. Koob, and A. Markou Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat - interactions between the two drugs Psychopharmacology 145 1999 283 294
109. H.P. Loomer, J.C. Saunders, and N.S. Kline A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer Psychiatr. Res. Rep. Am. Psychiatr. Assoc. 8 1957 129 141
110. J. Lopez-Ibor, J.D. Guelfi, Y. Pletan, A. Tournoux, and J.F. Prost Milnacipran and selective serotonin reuptake inhibitors in major depression Int. Clin. Psychopharmacol. 11 Suppl. 4 1996 S41 S46
111. A.L. Lopresti, G.L. Maker, S.D. Hood, and P.D. Drummond A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers Prog. Neuropsychopharmacol. Biol. Psychiatry 48 2014 102 111
112. C.Y. Lu, F. Zhang, M.D. Lakoma, J.M. Madden, D. Rusinak, R.B. Penfold, G. Simon, B.K. Ahmedani, G. Clarke, E.M. Hunkeler, B. Waitzfelder, A. Owen-Smith, M.A. Raebel, R. Rossom, K.J. Coleman, L.A. Copeland, and S.B. Soumerai Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study Br. Med. J. 348 2014 g3596
113. M. Marinelli, and P.V. Piazza Interaction between glucocorticoid hormones, stress and psychostimulant drugs Eur. J. Neurosci. 16 2002 387 394
114. A. Markou, and G.F. Koob Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations Physiol. Behav. 51 1992 111 119
115. M. Martinot, V. Bragulat, E. Artiges, F. Dolle, F. Hinnen, R. Jouvent, and J. Martinot Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation Am. J. Psychiatry 158 2001 314 316
116. J. Massana Reboxetine versus fluoxetine: an overview of efficacy and tolerability J. Clin. Psychiatry 59 Suppl. 14 1998 S8 S10
117. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med. 3 2006 e442
118. H.S. Mayberg, M. Liotti, S.K. Brannan, S. McGinnis, R.K. Mahurin, P.A. Jerabek, J.A. Silva, J.L. Tekell, C.C. Martin, J.L. Lancaster, and P.T. Fox Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness Am. J. Psychiatry 156 1999 675 682
119. B.S. McEwen, and T. Seeman Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load Ann. N. Y. Acad. Sci. 896 1999 30 47
120. B.S. McEwen Plasticity of the hippocampus: adaptation to chronic stress and allostatic load Ann. N. Y. Acad. Sci. 933 2001 265 277
121. C.R. McKittrick, A.M. Magarinos, D.C. Blanchard, R.J. Blanchard, B.S. McEwen, and R.R. Sakai Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites Synapse 36 2000 85 94
122. D. Mehta, C.L. Raison, B.J. Woolwine, E. Haroon, E.B. Binder, A.H. Miller, and J.C. Felger Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression Brain Behav. Immun. 31 2013 205 215
123. A.T. Michael-Titus, S. Bains, J. Jeetle, and R. Whelpton Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100 2000 681 684
124. E. Mignot A commentary on the neurobiology of the hypocretin/orexin system Neuropsychopharmacology 25 2001 S5 S13
125. A.H. Miller, E. Haroon, C.L. Raison, and J.C. Felger Cytokine targets in the brain: impact on neurotransmitters and neurocircuits Depress. Anxiety 30 2013 297 306
126. A.H. Miller, J.F. Jones, D.F. Drake, H. Tian, E.R. Unger, and G. Pagnoni Decreased basal ganglia activation in subjects with chronic fatigue syndrome: association with symptoms of fatigue PLoS One 9 2014 e98156
127. B.H. Miller, Z. Zeier, L. Xi, T.A. Lanz, S. Deng, J. Strathmann, D. Willoughby, P.J. Kenny, J.D. Elsworth, M.S. Lawrence, R.H. Roth, D. Edbauer, R.J. Kleiman, and C. Wahlestedt MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function Proc. Natl. Acad. Sci. USA 109 2012 3125 3130
128. P. Mitchell, D. Hadzi-Pavlovic, G. Parker, I. Hickie, K. Wilhelm, H. Brodaty, and P. Boyce Depressive psychomotor disturbance, cortisol, and dexamethasone Biol. Psychiatry 40 1996 941 950
129. B. Moghaddam, M.L. Bolinao, B. Stein-Behrens, and R. Sapolsky Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate Brain Res. 655 1994 251 254
130. M.E. Molliver Serotonergic neuronal systems: what their anatomic organization tells us about function J. Clin. Psychopharmacol. 7 1987 3S 23S
131. R. Mongeau, C. de Montigny, and P. Blier Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration Neuropsychopharmacology 10 1994 41 51
132. S.A. Montgomery Reboxetine: additional benefits to the depressed patient J. Psychopharmacol. 11 1997 S9 S15
133. J.A. Morón, I. Zakharova, J.V. Ferrer, G.A. Merrill, B. Hope, E.M. Lafer, Z.C. Lin, J.B. Wang, J.A. Javitch, A. Galli, and T.S. Shippenberg Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity J. Neurosci. 23 24 2003 8480 8488
134. C.J. Murray, K.F. Ortblad, and C. Guinovart T. Vos Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the global burden of disease study 2013 Lancet 384 9947 2014 1005 1070
135. L. Musazzi, M. Milanese, P. Farisello, S. Zappettini, D. Tardito, V.S. Barbiero, T. Bonifacino, A. Mallei, P. Baldelli, G. Racagni, M. Raiteri, F. Benfenati, G. Bonanno, and M. Popoli Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants PLoS One 5 2010 e8566
136. J. Nacher, and B.S. McEwen The role of N-methyl-d-asparate receptors in neurogenesis Hippocampus 16 2006 267 270
137. J. Nacher, E. Varea, J. Miguel Blasco-Ibanez, M.A. Gomez-Climent, E. Castillo-Gomez, C. Crespo, F.J. Martinez-Guijarro, and B.S. McEwen N-methyl-d-aspartate receptor expression during adult neurogenesis in the rat dentate gyrus Neuroscience 144 2007 855 864
138. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol. Psychiatry 59 2006 1151 1159
139. K.L. Nicholson, R.L. Balster, K. Golembiowska, M. Kowalska, J.P. Tizzano, P. Skolnick, and A.S. Basile Preclinical evaluation of the abuse potential of the analgesic bicifadine J. Pharmacol. Exp. Ther. 330 2009 236 248
140. D. Nutt, K. Demyttenaere, Z. Janka, T. Aarre, M. Bourin, P.L. Canonico, J.L. Carrasco, and S. Stahl The other face of depression, reduced positive affect: the role of catecholamines in causation and cure J. Psychopharmacol. 21 2007 461 471
141. J.C. O'Connor, C. Andre, Y. Wang, M.A. Lawson, S.S. Szegedi, J. Lestage, N. Castanon, K.W. Kelley, and R. Dantzer Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin J. Neurosci. 29 2009 4200 4209
142. J.E. Olijslagers, E.R. de Kloet, Y. Elgersma, G.M. van Woerden, M. Joels, and H. Karst Rapid changes in hippocampal CA1 pyramidal cell function via pre- as well as postsynaptic membrane mineralocorticoid receptors Eur. J. Neurosci. 27 2008 2542 2550
143. G.I. Papakostas, J.C. Nelson, S. Kasper, and H.J. Moller A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Eur. Neuropsychopharmacol. 18 2008 122 127
144. G.I. Papakostas, D.J. Nutt, L.A. Hallett, V.L. Tucker, A. Krishen, and M. Fava Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors Biol. Psychiatry 60 2006 1350 1355
145. J.M. Parish Violent dreaming and antidepressant drugs: or how paroxetine made me dream that I was fighting Saddam Hussein J. Clin. Sleep Med. 3 2007 529 531
146. N.E. Paterson, D.J. Balfour, and A. Markou Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats Nicotine Tob. Res. 10 2008 995 1008
147. V.A. Pavlov, and K.J. Tracey The cholinergic anti-inflammatory pathway Brain Behav. Immun. 19 6 2005 493 499
148. B.W. Penninx, Y. Milaneschi, F. Lamers, and N. Vogelzangs Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile BMC Med. 11 2013 129
149. C. Peyron, D.K. Tighe, A.N. van den Pol, L. de Lecea, H.C. Heller, J.G. Sutcliffe, and T.S. Kilduff Neurons containing hypocretin (orexin) project to multiple neuronal systems J. Neurosci. 18 1998 9996 10015
150. D. Popa, J. Cerdan, C. Reperant, B.P. Guiard, J.P. Guilloux, D.J. David, and A.M. Gardier A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain Eur. J. Pharmacol. 628 2010 83 90
151. H.M. Praag, J. Korf, J. Lakke, and T. Schut Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders Psychol. Med. 5 1975 138 146
152. M.L. Price, and I. Lucki Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor J. Neurosci. 21 8 2001 2833 2841
153. J. Prins, D.A. Denys, K.G. Westphal, G.A. Korte-Bouws, M.S. Quinton, R. Schreiber, L. Groenink, B. Olivier, and S.M. Korte The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats Eur. J. Pharmacol. 633 2010 55 61
154. J. Prins, B. Olivier, and S.M. Korte Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited Exp. Opin. Investig. Drugs 20 2011 1107 1130
155. J. Prins, K.G. Westphal, G.A. Korte-Bouws, M.S. Quinton, R. Schreiber, B. Olivier, and S.M. Korte The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialyis study in olfactory bulbectomized rats Pharmacol. Biochem. Behav. 97 2011 444 452
156. J. Prins, P.J. Kenny, I. Doomernik, R. Schreiber, B. Olivier, and S. Mechiel Korte The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats Eur. J. Pharmacol. 693 2012 51 56
157. S. Prisco, and E. Esposito Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area Br. J. Pharmacol. 116 1995 1923 1931
158. B. Qin, Y. Zhang, X. Zhou, P. Cheng, Y. Liu, J. Chen, Y. Fu, Q. Luo, and P. Xie Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability Clin. Ther. 36 2014 1087 1095 (e4)
159. J.J. Radley, A.B. Rocher, W.G. Janssen, P.R. Hof, B.S. McEwen, and J.H. Morrison Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress Exp. Neurol. 196 2005 199 203
160. C.L. Raison, and A.H. Miller Do cytokines really sing the blues? Cerebrum 2013 2013 10
161. S. Raskin, and R. Durst Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments Med. Hypotheses 75 2010 544 546
162. J.M. Reul, M.S. Labeur, D.E. Grigoriadis, E.B. De Souza, and F. Holsboer Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide Neuroendocrinology 60 1994 509 519
163. L. Romero, I. Hervas, and F. Artigas The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain Neurosci. Lett. 219 1996 123 126
164. B. Rypma, and M. D'Esposito The roles of prefrontal brain regions in components of working memory: effects of memory load and individual differences Proc. Natl. Acad. Sci. USA 96 1999 6558 6563
165. A.C. Sanders, A.J. Hussain, R. Hen, and X. Zhuang Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward Neuropsychopharmacology 32 2007 2321 2329
166. C.B. Saper, T.C. Chou, and J.K. Elmquist The need to feed: homeostatic and hedonic control of eating Neuron 36 2002 199 211
167. C.B. Saper, T.C. Chou, and T.E. Scammell The sleep switch: hypothalamic control of sleep and wakefulness Trends Neurosci. 24 2001 726 731
168. R.M. Sapolsky Stress hormones: good and bad Neurobiol. Dis. 7 2000 540 542
169. B.S. Sastry, and J.W. Phillis Inhibition of cerebral cortical neurones by a 5-hydroxytryptaminergic pathway from median raphe nucleus Can. J. Physiol. Pharmacol. 55 1977 737 743
170. G.J. Schaefer, and R.P. Michael Effects of amphetamine and nomifensine on intracranial self-stimulation discrimination behavior in rats Pharmacol. Biochem. Behav. 41 1992 391 397
171. K.A. Schoedel, D. Meier, B. Chakraborty, P.M. Manniche, and E.M. Sellers Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users Clin. Pharmacol. Ther. 88 2010 69 78
172. J. Schulkin, P.W. Gold, and B.S. McEwen Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load Psychoneuroendocrinology 23 1998 219 243
173. W. Schultz Multiple dopamine functions at different time courses Annu. Rev. Neurosci. 30 2007 259 288
174. W. Schultz Dopamine signals for reward value and risk: basic and recent data Behav. Brain Funct. 6 2010 24
175. J. Seppala, M. Vanhala, H. Kautiainen, J. Eriksson, O. Kampman, P. Mantyselka, H. Oksa, Y. Ovaskainen, M. Viikki, and H. Koponen Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study J. Affect. Disord. 136 2012 543 549
176. R.C. Shelton, and A.H. Miller Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression Prog. Neurobiol. 91 2010 275 299
177. K.I. Shulman, N. Herrmann, and S.E. Walker Current place of monoamine oxidase inhibitors in the treatment of depression CNS Drugs 27 2013 789 797
178. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa Preclinical and clinical pharmacology of DOV 216,303, a triple reuptake inhibitor CNS Drug Rev. 12 2006 123 134
179. E.M. Snoeren, J.G. Veening, B. Olivier, and R.S. Oosting Serotonin 1A receptors and sexual behavior in male rats: a review Pharmacol. Biochem. Behav. 121 2014 102 114
180. B. Sperner-Unterweger, C. Kohl, and D. Fuchs Immune changes and neurotransmitters: possible interactions in depression? Prog. Neuropsychopharmacol. Biol. Psychiatry 48 2014 268 276
181. S.M. Stahl, and A. Felker Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants CNS Spectr. 13 2008 855 870
182. S.M. Stahl, M.M. Grady, C. Moret, and M. Briley SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants CNS Spectr. 10 2005 732 747
183. S.M. Stahl, L. Zhang, C. Damatarca, and M. Grady Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder J. Clin. Psychiatry 64 Suppl. 14 2003 S6 S17
184. D.C. Steffens, K.R. Krishnan, and M.J. Helms Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis Depress. Anxiety 6 1997 10 18
185. B.A. Stein Behrens, W.J. Lin, and R.M. Sapolsky Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus J. Neurochem. 63 1994 596 602
186. D.J. Stein Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry CNS Spectr. 13 2008 561 565
187. J.W. Stewart, F.M. Quitkin, P.J. McGrath, and D.F. Klein Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions J. Affect. Disord. 86 2005 161 167
188. R.E. Strecker, J. Nalwalk, L.J. Dauphin, M.M. Thakkar, Y. Chen, V. Ramesh, L.B. Hough, and R.W. McCarley Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study Neuroscience 113 2002 663 670
189. V. Sturm, D. Lenartz, A. Koulousakis, H. Treuer, K. Herholz, J.C. Klein, and J. Klosterkotter The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders J. Chem. Neuroanat. 26 2003 293 299
190. C.J. Teter, S.E. McCabe, K. LaGrange, J.A. Cranford, and C.J. Boyd Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration Pharmacotherapy 26 2006 1501 1510
191. M.E. Thase, E. Frank, A.G. Mallinger, T. Hamer, and D.J. Kupfer Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors J. Clin. Psychiatry 53 1992 5 11
192. M.E. Thase, M.H. Trivedi, and A.J. Rush MAOIs in the contemporary treatment of depression Neuropsychopharmacology 12 1995 185 219
193. G. Tirabassi, M. Boscaro, and G. Arnaldi Harmful effects of functional hypercortisolism: a working hypothesis Endocrine 46 2014 370 386
194. K.J. Tracey The inflammatory reflex Nature 420 6917 2002 853 859.
195. P. Tran, P. Skolnick, P. Czobor, N.Y. Huang, M. Bradshaw, A. McKinney, and M. Fava Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial J. Psychiatr. Res. 46 2012 64 71
196. L.K. Tremblay, C.A. Naranjo, L. Cardenas, N. Herrmann, and U.E. Busto Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine Arch. Gen. Psychiatry 59 2002 409 416
197. M.H. Trivedi, M. Fava, S.R. Wisniewski, M.E. Thase, F. Quitkin, D. Warden, L. Ritz, A.A. Nierenberg, B.D. Lebowitz, M.M. Biggs, J.F. Luther, K. Shores-Wilson, and A.J. Rush Medication augmentation after the failure of SSRIs for depression N. Engl. J. Med. 354 2006 1243 1252
198. F.J. van der Staay, T. Schuurman, C.G. van Reenen, and S.M. Korte Emotional reactivity and cognitive performance in aversively motivated tasks: a comparison between four rat strains Behav. Brain Funct. 5 2009 50
199. F. van Heesch, J. Prins, J.P. Konsman, G.A. Korte-Bouws, K.G. Westphal, J. Rybka, B. Olivier, A.D. Kraneveld, and S.M. Korte Lipopolysaccharide increases degradation of central monoamines: an in vivo microdialysis study in the nucleus accumbens and medial prefrontal cortex of mice Eur. J. Pharmacol. 725 2014 55 63
200. F. van Heesch, J. Prins, J.P. Konsman, K.G. Westphal, B. Olivier, A.D. Kraneveld, and S.M. Korte Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study Brain Behav. Immun. 29 2013 98 103
201. D.H. van Raalte, D.M. Ouwens, and M. Diamant Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur. J. Clin. Investig. 39 2009 81 93
202. J.G. Veening, T.R. de Jong, M.D. Waldinger, S.M. Korte, and B. Olivier The role of oxytocin in male and female reproductive behavior Eur. J. Pharmacol. 2014 10.1016/j.ejphar.2014.07.045 (Epub ahead of print)
203. F. van Heesch, J. Prins, G.A. Korte-Bouws, K.G. Westphal, S. Lemstra, B. Olivier, A.D. Kraneveld, and S.M. Korte Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice Behav. Brain Res. 253 2013 191 195
204. C. Venero, and J. Borrell Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats Eur. J. Neurosci. 11 1999 2465 2473
205. N.D. Volkow, G. Wang, J.S. Fowler, J. Logan, M. Gerasimov, L. Maynard, Y. Ding, S.J. Gatley, A. Gifford, and D. Franceschi Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain J. Neurosci. 21 2001 RC121
206. N.D. Volkow, G.J. Wang, M.W. Fischman, R.W. Foltin, J.S. Fowler, N.N. Abumrad, S. Vitkun, J. Logan, S.J. Gatley, N. Pappas, R. Hitzemann, and C.E. Shea Relationship between subjective effects of cocaine and dopamine transporter occupancy Nature 386 1997 827 830
207. S.M. Williams, and P.S. Goldman-Rakic Widespread origin of the primate mesofrontal dopamine system Cereb. Cortex 8 1998 321 345
208. P. Willner The mesolimbic dopamine system as a target for rapid antidepressant action Int. Clin. Psychopharmacol. 12 Suppl. 3 1997 S7 S14
209. J.P. Wisor, S. Nishino, I. Sora, G.H. Uhl, E. Mignot, and D.M. Edgar Dopaminergic role in stimulant-induced wakefulness J. Neurosci. 21 2001 1787 1794
210. E.H. Wong, M.S. Sonders, S.G. Amara, P.M. Tinholt, M.F. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori, N. Carfagna, and R.A. McArthur Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol. Psychiatry 47 2000 818 829
211. M.L. Wong, M.A. Kling, P.J. Munson, S. Listwak, J. Licinio, P. Prolo, B. Karp, I.E. McCutcheon, T.D. Geracioti Jr.; M.D. DeBellis, K.C. Rice, D.S. Goldstein, J.D. Veldhuis, G.P. Chrousos, E.H. Oldfield, S.M. McCann, and P.W. Gold Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone Proc. Natl. Acad. Sci. USA 97 2000 325 330
212. P.B. Wood Mesolimbic dopaminergic mechanisms and pain control Pain 120 2006 230 234
213. R.J. Wurtman, and J.J. Wurtman Brain serotonin, carbohydrate-craving, obesity and depression Obes. Res. 3 Suppl. 4 1995 477S 480S
214. E.Y. Yuen, W. Liu, I.N. Karatsoreos, J. Feng, B.S. McEwen, and Z. Yan Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory Proc. Natl. Acad. Sci. USA 106 2009 14075 14079
215. H. Zheng, and H.R. Berthoud Eating for pleasure or calories Curr. Opin. Pharmacol. 7 2007 607 612
216. E.A. Zeller, and J. Barsky In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine Proc. Soc. Exp. Biol. Med. 81 1952 459 461
217. C.B. Zhu, R.D. Blakely, and W.A. Hewlett The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters Neuropsychopharmacology 31 10 2006 2121 2131
218. C.B. Zhu, J.A. Steiner, J.L. Munn, L.C. Daws, W.A. Hewlett, and R.D. Blakely Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors J. Pharmacol. Exp. Ther. 322 1 2007 332 340
219. C.B. Zhu, K.M. Lindler, A.W. Owens, L.C. Daws, R.D. Blakely, and W.A. Hewlett Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters Neuropsychopharmacology 35 2010 2510 2520